Angiogenesi
Gli inibitori dell'angiogenesi sono composti che interferiscono con la formazione di nuovi vasi sanguigni, un processo cruciale nella crescita e metastasi del cancro. Inibendo l'angiogenesi, questi composti possono limitare l'apporto di sangue ai tumori, rallentandone o arrestando la crescita. Gli inibitori dell'angiogenesi sono fondamentali nella ricerca sul cancro e nello sviluppo terapeutico, offrendo approfondimenti sui meccanismi di progressione tumorale e potenziali trattamenti per il cancro e altre malattie legate all'angiogenesi. Presso CymitQuimica, offriamo un'ampia gamma di inibitori dell'angiogenesi di alta qualità per supportare le tue ricerche in oncologia e biologia vascolare.
Sottocategorie di "Angiogenesi"
- BTK(158 prodotti)
- Bcr-Abl(113 prodotti)
- EGFR(598 prodotti)
- FAK(72 prodotti)
- FLT(90 prodotti)
- Recettore del fattore di crescita dei fibroblasti (FGFR)(182 prodotti)
- JAK(246 prodotti)
- PDGFR(126 prodotti)
- RAAS(90 prodotti)
- Src(81 prodotti)
- Syk(37 prodotti)
- Trombina(53 prodotti)
- VDA(2 prodotti)
- VEGFR(250 prodotti)
Mostrare 6 più sottocategorie
Trovati 2040 prodotti di "Angiogenesi"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
WZH-15-125
CAS:WZH-15-125 is a potent ALK inhibitor capable of overcoming resistance, particularly with complex ALK mutations. It exhibits an IC50 of 101.7 nM against the highly recalcitrant Lorlatinib-resistant G1202R/L1196M mutation. Additionally, WZH-15-125 can serve as a PROTAC target protein ligand for synthesizing PROTACWZH-17-002. This compound is applicable in non-small cell lung cancer research.Formula:C33H45BrN8O5SColore e forma:SolidPeso molecolare:745.73DHFR-IN-4
CAS:DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with anti-tumour activity, inhibits EGFR and HER2 and can be used to study pancreatic cancer.Formula:C18H21N5O2SPurezza:99.41%Colore e forma:SolidPeso molecolare:371.46D-69491 hydrochloride
CAS:D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Formula:C25H26Cl2FN7O3Colore e forma:SolidPeso molecolare:562.42EGFR-IN-3
EGFR-IN-3 is an EGFR inhibitor with antitumor activity.EGFR-IN-3 inhibits EGFRwt-TK, induces apoptosis (cell death), and can block cells in the G2/M phase.Formula:C24H18F4N6O2SPurezza:98.1%Colore e forma:SolidPeso molecolare:530.57PPD-Q
CAS:7PPD-Q is a substituted p-phenylenediamine antioxidant derivative. It exhibits toxicity towards the bacterium V. fischeri (EC50= 14.9 mg/L).Formula:C19H24N2O2Colore e forma:SolidPeso molecolare:312.41Tarloxotinib bromide
CAS:Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.Formula:C24H24Br2ClN9O3Purezza:99.52%Colore e forma:SolidPeso molecolare:681.77Pred17
Pred17 is an effective EGFR inhibitor with potential applications in lung cancer research.Formula:C27H22BN3OColore e forma:SolidPeso molecolare:415.29EGFR-IN-125
CAS:<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Formula:C30H26N8OColore e forma:SolidPeso molecolare:514.58BTK-IN-34
CAS:BTK-IN-34 (compound 9h) functions as a selective BTK inhibitor, exhibiting antiproliferative effects in RAMOS cells by specifically targeting pBTK (Tyr223) while sparing upstream proteins such as Lyn and Syk in the BCR signaling pathway [1].Formula:C22H29N3O4SPeso molecolare:431.55RET-IN-14
CAS:RET-IN-14 inhibits RET (IC50: <0.51-9.3 nM) & BTK (C481S) (IC50: 9.2-15 nM), promising for tumor research.Formula:C24H23FN8O4Colore e forma:SolidPeso molecolare:506.49EGFR-IN-58
EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.Formula:C31H30FN7OColore e forma:SolidPeso molecolare:535.61FLT3-IN-32
CAS:FLT3-IN-32 is a potent FLT3 inhibitor with high selectivity, effectively suppressing FLT3 activating mutations and inducing apoptosis. It demonstrates good tolerance in non-tumor-bearing mice. In NOD/SCID mice loaded with MV4-11 cells, FLT3-IN-32 exhibits outstanding antitumor efficacy, significantly extending mouse survival. FLT3-IN-32 is applicable for acute myeloid leukemia research.Formula:C28H29N5O5Colore e forma:SolidPeso molecolare:515.56HDHD4-IN-1
CAS:HDHD4-IN-1 (compound 3) is an inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) with an IC50 value of 11 μM. It is utilized in the research of neurological disorders.Formula:C12H22NO11PColore e forma:SolidPeso molecolare:387.28(Rac)-Ibrutinib alkyne
CAS:(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. This compound effectively inhibits B cell receptor signaling functions, with an IC50 of 9 nM for calcium flux inhibition in Ramos cells. (Rac)-Ibrutinib alkyne is applicable in research on diseases such as rheumatoid arthritis.Formula:C25H22N6O2Colore e forma:SolidPeso molecolare:438.48CEP-11981
CAS:CEP-11981 is an orally active TIE2/pan-VEGFR inhibitor with broad tyrosine kinase inhibitory activity, antitumour and anti-angiogenic, refractory solid tumours.Formula:C28H27N7OPurezza:99.58%Colore e forma:SolidPeso molecolare:477.56Multi-kinase inhibitor 4
CAS:Multi-kinase inhibitor 4 (compound 14) serves as an orally effective inhibitor targeting FLT1, KDR, FLT3, FLT4, PDGFRα, and PDGFRβ, exhibiting IC50 values of 1.97 nM, 1.04 nM, 0.33 nM, 1.44 nM, 0.18 nM, and 0.89 nM respectively. This compound plays a crucial role in cancer research.Formula:C25H24N6O2Colore e forma:SolidPeso molecolare:440.50YSY01A
CAS:YSY01A is a proteasome inhibitor that suppresses cancer cell survival by inducing apoptosis (Apoptosis). It demonstrates IC50 values against various cell lines such as HEK293T, A549, MCF-7, MGC-803, and PC-3M with values of 51.01, 9.21, 5.21, 8.9, and 35.4 nM respectively. Additionally, YSY01A serves as a degrader of gp130 and JAK2, eliminating constitutive STAT3 signaling in human A549 lung cancer cells by downregulating gp130 and JAK2. YSY01A holds potential for research in cancer therapeutics.Formula:C29H38BN5O5Colore e forma:SolidPeso molecolare:547.45Tuspetinib dihydrochloride
CAS:Tuspetinib (HM43239) dihydrochloride is a selective FLT3 inhibitor with oral bioactivity, exhibiting IC50 values of 1.1 nM for FLT3 wild type, 1.8 nM for FLT3ITD mutant type, and 1.0 nM for FLT3D835Y mutant type. As a reversible type I inhibitor, it directly suppresses FLT3 kinase activity and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib dihydrochloride inhibits the proliferation of leukemia cells and induces apoptosis (apoptosis).Formula:C29H35Cl3N6Colore e forma:SolidPeso molecolare:573.99Protein Kinase Inhibitor 12
CAS:<p>Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.</p>Formula:C14H14N4OSPurezza:98.06%Colore e forma:SolidPeso molecolare:286.35Anticancer agent 69
Anticancer agent 69 targets PC3 cells (IC50=26 nM), raises ROS, lowers EGFR, and induces apoptosis.Formula:C19H26N8SColore e forma:SolidPeso molecolare:398.53SILA-123
CAS:<p>SILA-123, an inhibitor of FLT3 (FLT3-WT: IC50=2.1 nM; FLT3-ITD: IC50=1.0 nM), induces cell apoptosis by hindering the cell cycle progression at the G0/G1 phase through the suppression of FLT3 phosphorylation and its downstream signaling pathways. This compound is utilized in the study of acute myeloid leukemia.</p>Formula:C24H25N5O2Colore e forma:SolidPeso molecolare:415.49Multi-kinase inhibitor 3
CAS:<p>Multi-kinase inhibitor 3 (compound 12) is an orally active and effective multikinase (multikinase) inhibitor, demonstrating potent IC50 values against FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, and PDGFRβ, at 1.59, 1.23, 1.19, 0.59, 0.22, and 1.15 nM respectively. This compound exhibits anti-proliferative and anticancer activities.</p>Formula:C26H26N6O2Colore e forma:SolidPeso molecolare:454.52CLM3
CAS:<p>CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways.</p>Formula:C21H21N5Colore e forma:SolidPeso molecolare:343.43VEGFR-2-IN-38
CAS:VEGFR-2-IN-38 (compound 3) acts as a potential inhibitor of the vascular endothelial growth factor receptor-2 [1].Formula:C17H12N4SColore e forma:SolidPeso molecolare:304.37SYHA1815
CAS:SYHA1815, an orally active RET inhibitor (IC50=0.9 nmol/L), demonstrates antitumor activity. It exhibits greater selectivity for RET over KDR (IC50=15.9 nmol/L). SYHA1815 operates by downregulating c-Myc, arresting the G1 cell cycle, and inhibiting RET-driven cell proliferation.Formula:C27H26ClF4N5OColore e forma:SolidPeso molecolare:547.98I194496
CAS:<p>I194496 is an effective inhibitor of cystathionine γ-lyase (CSE) with an IC50 value of 0.79 mM. It inhibits the growth of human TNBC cells by dual targeting the PI3K/Akt and Ras/Raf/ERK pathways. Additionally, I194496 suppresses the metastasis of human TNBC cells by downregulating the Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways.</p>Formula:C28H23F2N5O5SColore e forma:SolidPeso molecolare:579.58ALKBH5-IN-3
CAS:ALKBH5-IN-3 (Compound 20m) is a selective ALKBH5 inhibitor (IC50=21 nM), effectively stabilizes ALKBH5 in HepG2 cells and elevates m6A levels in intact cells.Formula:C11H7F3N2O3Purezza:98.32%Colore e forma:SolidPeso molecolare:272.18Squalamine
CAS:Squalamine is an aminosterol compound, with potent broad spectrum antiviral activity.Formula:C34H65N3O5SPurezza:98%Colore e forma:SolidPeso molecolare:627.96Ki11502
CAS:Ki11502 is a multi-target receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGFβ/α receptors (with an IC50 of less than 10 nM). It specifically suppresses PDGFβ receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Additionally, Ki11502 induces apoptosis and exhibits significant antiproliferative effects against specific leukemia subgroups, including those with Imatinib-resistant mutations. It is particularly suitable for studying the role of PDGF in vascular diseases and the involvement of proteoglycans in atherosclerosis.Formula:C26H23N3O4SPeso molecolare:473.54Lazertinib mesylate
CAS:<p>Lazertinib (mesylate) (YH25448 (mesylate); GNS-1480 (mesylate)) is an orally active EGFR inhibitor capable of crossing the blood-brain barrier. It suppresses the p-EGFR, p-AKT, and p-ERK signaling pathways, leading to apoptosis. Lazertinib (mesylate) demonstrates antitumor activity in the H1975-luc BM xenograft model in mice and is applicable for researching non-small cell lung cancer.</p>Formula:C31H38N8O6SPeso molecolare:650.75PNU-145156E
CAS:PNU-145156E is a noncytotoxic molecule inhibiting growth and angiogenic factors, suppress tumor angiogenesis, support anti-angiogenic research strategies.Formula:C45H40N10O17S4Colore e forma:SolidPeso molecolare:1121.12Tyk2-IN-17
CAS:<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>Formula:C20H20F2N8OColore e forma:SolidPeso molecolare:426.42JAK1/TYK2-IN-4
CAS:JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].Formula:C17H23N7OColore e forma:SolidPeso molecolare:341.41EGFR-IN-160
CAS:EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formula:C15H12N2O4Colore e forma:SolidPeso molecolare:284.27Tyk2-IN-14
CAS:Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].Formula:C22H21N9O2Colore e forma:SolidPeso molecolare:443.46Tyk2-IN-15
CAS:<p>Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].</p>Formula:C21H25F2N7OColore e forma:SolidPeso molecolare:429.47JAK/HDAC-IN-3
CAS:JAK/HDAC-IN-3 (13a), a dual inhibitor of JAK and HDAC, exhibits IC50 values of 25.36 nM for JAK2, 0.2 μM for HDAC, and 0.43 μM for HDAC1, respectively [1].Formula:C28H37FN6O5SColore e forma:SolidPeso molecolare:588.69EG31
CAS:EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.Formula:C30H13Br2N3O6Colore e forma:SolidPeso molecolare:671.25mG2N001
CAS:mG2N001, a negative allosteric modulator (NAM) of the metabotropic glutamate receptor mGluR2, has an IC50 of 93 nM and binds to mGluR2 as an antagonist with a Ki of 63 nM. This compound is microparticle- and plasma-stable, and its radioisotope [11C] mG2N001 can be utilized in PET imaging. [11C] mG2N001 exhibits good brain heterogeneity and penetration, selectively accumulating in mGluR2-rich regions to produce high-contrast brain images [1].Formula:C18H19FN2O3Colore e forma:SolidPeso molecolare:330.35MK-8457
CAS:MK-8457 is a dual inhibitor of SYK and ZAP70, valuable for rheumatoid arthritis research [1].Formula:C24H25F3N4O3SColore e forma:SolidPeso molecolare:506.54CDDD11-8
CAS:CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].Formula:C24H26N6Colore e forma:SolidPeso molecolare:398.50Pyk2-IN-2
CAS:Pyk2-IN-2 (compound 13j) acts as a Pyk2 inhibitor, exhibiting an IC 50 value of 0.608 μM for FAK kinase [1].Formula:C27H27N7OColore e forma:SolidPeso molecolare:465.55PP487
CAS:PP487 is a dual tyrosine kinase/PI(3)K inhibitor, exhibiting IC50 values of 0.017 μM, 0.072 μM, 0.004 μM, 0.01 μM, 0.55 μM, 0.22 μM, and < 0.01 μM against DNA-PK, mTOR, Hck, Src, EGFR, EphB4, and PDGFR, respectively. It is applicable in cancer research [1].Formula:C14H14BrN5OColore e forma:SolidPeso molecolare:348.2JAK3/BTK-IN-7
CAS:JAK3/BTK-IN-7 (XL-12), characterized as a JAK3/BTK inhibitor, exhibits IC 50 values of 2 nM and 14 nM for JAK3 and BTK respectively. This compound demonstrates anti-inflammatory properties and is applicable in research related to rheumatoid arthritis [1].Formula:C29H30N8O4Colore e forma:SolidPeso molecolare:554.6TQ-3959
CAS:TQ-3959 is an orally active BTKPROTAC degrader, with a DC50 of 14.6 nM. It exhibits antiproliferative activity against both wild-type BTK and BTK C481S mutant cell lines. TQ-3959 demonstrates tumor growth inhibition in female NOD-SCID mice with TMD-8 xenografts. This compound is applicable in the study of B-cell malignancies, such as lymphoma.Formula:C40H47N11O5Colore e forma:SolidPeso molecolare:761.87Brefeldin A 4-O-nicotinate
CAS:Brefeldin A 4-O-nicotinate (CHNQD-01228) is a dual inhibitor of Arf1 and BMX proteins with an IC50 value of 0.22 μM for T24 cell proliferation. It also suppresses T24 cell migration and colony formation in a dose-dependent manner, induces G1 phase arrest, and triggers apoptosis. By targeting BMX proteins, it inhibits the AKT/p-AKT and STAT3/p-STAT3 signaling pathways, while also inhibiting Arf1 proteins to eliminate bladder cancer stem cells and activate antitumor immunity, thus exhibiting anticancer activity. Brefeldin A 4-O-nicotinate is applicable in research related to bladder cancer.Formula:C22H27NO5Colore e forma:SolidPeso molecolare:385.453BTK-IN-6
BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.Formula:C23H22FN5O3Colore e forma:SolidPeso molecolare:435.45JAK2/FLT3-IN-1 TFA
JAK2/FLT3-IN-1 (TFA), an oral JAK2/FLT3 inhibitor, shows anticancer properties; IC50: JAK2 (0.7 nM), FLT3 (4 nM), JAK1 (26 nM), JAK3 (39 nM).Formula:C27H35F4N7O3Colore e forma:SolidPeso molecolare:581.61VEGFR-IN-3
CAS:VEGFR-IN-3 inhibits cancer cell growth (OVCAR-4, MDA-MB-468) with IC50s: 0.29, 0.35μM. Used in cancer research.Formula:C27H28N2O6Colore e forma:SolidPeso molecolare:476.52HER2-IN-12
HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.Formula:C17H18BrN5O2SColore e forma:SolidPeso molecolare:436.33JAK-2/3-IN-3
JAK-2-/3-IN-3 (ST4j) is a potent JAK2/3 inhibitor for leukemia research, with IC50s: JAK2, 13 nM; JAK3, 14.86 nM; induces apoptosis.Formula:C13H10Cl2N4O2Colore e forma:SolidPeso molecolare:325.15Tofacitinib Prodrug-1
Tofacitinib Prodrug-1: an oral prodrug reducing Tofacitinib's side effects, treats ulcerative colitis in mice effectively with low toxicity.Formula:C36H39ClN10O7Colore e forma:SolidPeso molecolare:759.21EGFR-IN-47
EGFR-IN-47: strong oral EGFRL858R/T790M/C797S blocker, induces cell death; promising for NSCLC research. IC50: 0.01 μM.Formula:C29H35N7Colore e forma:SolidPeso molecolare:481.64VEGFR-2-IN-18
VEGFR-2-IN-18 is a potent VEGFR-2 inhibitor with a 60 nM IC50, promoting cell apoptosis and anticancer effects.Formula:C20H13ClN4O2Colore e forma:SolidPeso molecolare:376.8AKN-028 acetate
AKN-028 acetate: an oral TK inhibitor for AML research, targets FLT3 with IC50 of 6 nM, inhibits autophosphorylation, and induces apoptosis.Formula:C19H18N6O2Colore e forma:SolidPeso molecolare:362.39EGFR/HER2-IN-4
EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.Colore e forma:SolidHDAC-IN-35
HDAC-IN-35 (Compound 14) is an effective and selective inhibitor of VEGFR-2 and HDAC, with IC50 values of 13.2 and 0.166 μM for VEGFR-2 and HDAC6, respectively.Formula:C17H13ClF3N3O3Colore e forma:SolidPeso molecolare:399.75JAK3-IN-11
CAS:JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.Formula:C23H23N5O2Colore e forma:SolidPeso molecolare:401.46FAK-IN-21
CAS:FAK-IN-21 (compound 9) is a FAK inhibitor with an IC50 value of 37.52 nM. It inhibits cell growth and the phosphorylation of FAK, making it useful for research into diffuse gastric cancer.Formula:C22H22F2N8O3SColore e forma:SolidPeso molecolare:516.52VEGFR-2-IN-17
VEGFR-2-IN-17 (15a) is a potent VEGFR-2 inhibitor with an IC50 of 67.25 nM, showing significant antitumor effects.Formula:C21H14ClN3O2Colore e forma:SolidPeso molecolare:375.81VEGFR-2/DHFR-IN-2
VEGFR-2/DHFR-IN-2 inhibits VEGFR-2 & DHFR (IC50: 0.623 & 9.085 μM), toxic to C26, HepG2, MCF7 cells (IC50: 3.59-8.38 μM), promising for cancer study.Formula:C21H21NO4Colore e forma:SolidPeso molecolare:351.4FAK inhibitor 7
CAS:FAK inhibitor7, a potent FAK inhibitor, demonstrates an IC50 of 3.58 nM. This compound effectively inhibits downstream signaling cascades of FAK (such as Src and AKT), which leads to cell cycle arrest at the G0/G1 phase and induces cytotoxic autophagy in ovarian cancer cells. Additionally, FAK inhibitor7 has been shown to suppress tumor metastasis and growth in ovarian cancer mouse models.Formula:C32H37N7O3Colore e forma:SolidPeso molecolare:567.68M-COPA
CAS:M-COPA disrupts Golgi, blocks MET & Arf1 activation, and inhibits angiogenesis via VEGFR & NF-kB pathways.Formula:C25H34N2O2Colore e forma:SolidPeso molecolare:394.55VEGFR-2/DHFR-IN-1
Compound 8b inhibits VEGFR-2/DHFR, combats various bacteria, and fights cancer cells.Formula:C20H18ClNO4Colore e forma:SolidPeso molecolare:371.81VEGFR-2-IN-15
VEGFR-2-IN-15 (Compound 14b) is a potent inhibitor of VEGFR-2. VEGFR-2-IN-15 inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.Formula:C23H18ClN3O4SColore e forma:SolidPeso molecolare:467.92JAK1/TYK2-IN-3
JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.Colore e forma:SolidSi306
CAS:Si306, an Src inhibitor, exhibits antitumor activity by reducing the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM).Formula:C25H26BrClN6OSColore e forma:SolidPeso molecolare:573.94EGFR/HER2-IN-7
EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.Formula:C19H21N3O2SColore e forma:SolidPeso molecolare:355.45GNE-431
CAS:GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.Formula:C30H32N10O2Colore e forma:SolidPeso molecolare:564.64FLT3-ITD-IN-3
CAS:FLT3-ITD-IN-3 (13v) is an orally active inhibitor of FLT3-ITD (internal tandem duplication of FLT3), which works by blocking FLT3 signaling. This inhibition leads to cell cycle arrest in the G0/G1 phase and induces apoptosis. The compound is currently employed in studies related to acute myeloid leukemia (AML).Formula:C27H21ClF2N6O5Colore e forma:SolidPeso molecolare:582.943JAK-IN-23
"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."Formula:C23H22Cl2N4OColore e forma:SolidPeso molecolare:441.35FGFR-IN-5
CAS:FGFR-IN-5 is a potent inhibitor of FGFR. FGFR-IN-5 has potential for research in cancer diseases.Formula:C25H22N6O3Colore e forma:SolidPeso molecolare:454.48EGFR-IN-35
CAS:EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Formula:C25H24ClN7O2Colore e forma:SolidPeso molecolare:489.96VEGFR-2-IN-12
VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent inhibitor of VEGFR-2 (IC50: 0.037 μM). VEGFR-2-IN-12 has anti-tumour effects.Formula:C22H24N6O3SColore e forma:SolidPeso molecolare:452.53EGFR-IN-45
<p>EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.</p>Formula:C28H23N7OColore e forma:SolidPeso molecolare:473.53WS-11
CAS:WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.Formula:C26H22FN9O2Colore e forma:SolidPeso molecolare:511.51FLT3/TrKA-IN-1
FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.Formula:C28H30N4O2Colore e forma:SolidPeso molecolare:454.56CEE321
CAS:CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.Formula:C18H16ClN5OColore e forma:SolidPeso molecolare:353.806DDO-02267
CAS:<p>DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.</p>Formula:C18H12N2O7SColore e forma:SolidPeso molecolare:400.362EGFR/HER2-IN-8
EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.Formula:C16H16N4O2SColore e forma:SolidPeso molecolare:328.39VEGFR-2-IN-25
CAS:VEGFR-2-IN-25 (compound 5d) is a potent inhibitor of VEGFR-2 (IC50: 12.1 nM).Formula:C24H22N6O2Colore e forma:SolidPeso molecolare:426.47LT-850-166
LT-850-166 is a potent inhibitor of FLT3 and has shown efficacy in overcoming a wide range of FLT3 mutations.Formula:C30H29Cl2N7OColore e forma:SolidPeso molecolare:574.5Sacibertinib
CAS:Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Formula:C32H31ClN6O4Colore e forma:SolidPeso molecolare:599.08EGFR-IN-34
EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.Formula:C26H27ClN6O2Colore e forma:SolidPeso molecolare:490.98Hypothemycin
CAS:Hypothemycin, a fungal polyketide, inhibits multiple kinases (VEGFR, MEK, FLT-3, PDGFR, ERK) with Kis ranging from 10 nM to 2.4 μM.Formula:C19H22O8Purezza:98%Colore e forma:SolidPeso molecolare:378.37HER2-IN-6
CAS:<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Formula:C26H32N8O3Colore e forma:SolidPeso molecolare:504.58FAK-IN-4
FAK-IN-4 (Compound 7d) has anticancer activities that can induce cell apoptosis. FAK-IN-4 is potential inhibitor of FAK [1].Formula:C20H22N4OColore e forma:SolidPeso molecolare:334.41EGFR-IN-24
EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).Formula:C30H35FN6O3Colore e forma:SolidPeso molecolare:546.64BTK-IN-7
BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.Formula:C30H32N6O4Colore e forma:SolidPeso molecolare:540.61EGFR/HER2-IN-6
EGFR/HER2-IN-6 is a dual inhibitor of EGFR, HER2, and DHFR with IC50s: 0.122, 0.078, and 0.585 μM, showing anticancer potential and selectivity.Formula:C18H21N5O3SColore e forma:SolidPeso molecolare:387.46FGFR4-IN-6
FGFR4-IN-6: covalent, reversible FGFR4 blocker, 5.4 nM IC50, good oral bioavailability, reduces Hep3B2.1-7 tumors in mice, low toxicity.Formula:C31H33N7O4Colore e forma:SolidPeso molecolare:567.64FGFR4-IN-9
FGFR4-IN-9 is a selective inhibitor of FGFR4 (IC50: 75.3 nM) that effectively inhibits the growth and angiogenesis of hepatocellular carcinoma cells.Formula:C24H22ClF3N4O4Colore e forma:SolidPeso molecolare:522.9EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Formula:C27H31ClN7O3PColore e forma:SolidPeso molecolare:568.01E7090 succinate
CAS:E7090 succinate inhibits FGFR1, FGFR2, and FGFR3 with IC50: 0.71, 0.50, 1.2 nM; less so FGFR4 at 120 nM.Formula:C76H92N10O24Colore e forma:SolidPeso molecolare:1529.60Antiallergic agent-1
Antiallergic agent-1, an Src family kinase inhibitor, is a new and valuable lead compound with potential as an anti-allergic agent.Formula:C27H19F6N5OColore e forma:SolidPeso molecolare:543.46TTT 3002
CAS:TTT 3002: oral FLT3 inhibitor for AML research, blocks D835 mutations, potent at 0.2 nM IC50.Formula:C27H23N5O3Colore e forma:SolidPeso molecolare:465.50JAK2 JH2 binder-1
CAS:JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.Formula:C29H25N7O6SColore e forma:SolidPeso molecolare:599.62FAK-IN-23
CAS:<p>FAK-IN-23 (Compound II) is an inhibitor of focal adhesion kinase (FAK).</p>Formula:C32H38F3N5O8Colore e forma:SolidPeso molecolare:677.668EGFR-IN-18
EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).Formula:C33H28N6O3SColore e forma:SolidPeso molecolare:588.68HSN748
CAS:HSN748 is an analog of ponatinib and acts as a multi-kinase inhibitor. It exhibits inhibitory activity against kinases such as FLT3, ABL1, RET, PDGFRα/β, MNK1, and MNK2. HSN748 can suppress the growth of chronic myeloid leukemia and acute myeloid leukemia cell lines, making it a useful compound in leukemia research.Formula:C27H24F3N7OColore e forma:SolidPeso molecolare:519.521
